ORPOF (OSE Immunotherapeutics) Long-Term Debt: $25.57 Mil (As of Dec. 2025)


ORPOF OSE Immunotherapeutics SA ORPOF
41 GF Score
Price $4.43
GF Value $3.35
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is OSE Immunotherapeutics Long-Term Debt?

OSE Immunotherapeutics ORPOF 41 Long-Term Debt is $25.57 Mil as of Dec. 2025. GuruFocus rates ORPOF with a GF Score™ of 41/100 and a GF Value™ of $3.35 (Significantly Overvalued). The stock has 6 warning signs investors should review.

OSE Immunotherapeutics's Long-Term Debt for the quarter that ended in Dec. 2025 was $25.57 Mil.

OSE Immunotherapeutics's quarterly Long-Term Debt declined from Dec. 2024 ($37.34 Mil) to Jun. 2025 ($33.78 Mil) and declined from Jun. 2025 ($33.78 Mil) to Dec. 2025 ($25.57 Mil).

OSE Immunotherapeutics's annual Long-Term Debt declined from Dec. 2023 ($38.72 Mil) to Dec. 2024 ($37.34 Mil) and declined from Dec. 2024 ($37.34 Mil) to Dec. 2025 ($25.57 Mil).

OSE Immunotherapeutics  (OTCPK:ORPOF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

OSE Immunotherapeutics Long-Term Debt Related Terms

OSE Immunotherapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for OSE Immunotherapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OSE Immunotherapeutics Long-Term Debt Chart

OSE Immunotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.41 39.44 38.72 37.34 25.57

OSE Immunotherapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.72 39.99 37.34 33.78 25.57
ORPOF
41GF Score
OSE Immunotherapeutics SA ORPOF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $25.57 Mil mean?
OSE Immunotherapeutics (ORPOF) has a Long-Term Debt of $25.57 Mil as of Dec. 2025.
Is OSE Immunotherapeutics' Long-Term Debt too high?
OSE Immunotherapeutics' current Long-Term Debt is $25.57 Mil. Overall, OSE Immunotherapeutics has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' Long-Term Debt compare to VRTX and REGN?
OSE Immunotherapeutics' Long-Term Debt of $25.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. OSE Immunotherapeutics's current Long-Term Debt is $25.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, OSE Immunotherapeutics (ORPOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.35, compared to a current price of $4.43 — trading 32.2% above its estimated fair value. The current Long-Term Debt is $25.57 Mil. OSE Immunotherapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For OSE Immunotherapeutics (ORPOF), the current Long-Term Debt is $25.57 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?

Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued. The current stock price of $4.43 is trading 32.2% above its estimated GF Value™ of $3.35. GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.

Key valuation signals for ORPOF:

  • Long-Term Debt: $25.57 Mil
  • GF Value™: $3.35 vs. price of $4.43 (32.2% above fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OSE Immunotherapeutics Business Description

Address 22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
41GF Score

Get the complete analysis for ORPOF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.43
Price
$3.35
GF Value